您的位置：
首页
>
农业专利
>
详情页
Method for selectively inhibiting the activity of ACAT1 in the treatment of alzheimers disease
专利权人:
Ta-Yuan Chang
发明人:
Ta-Yuan Chang,Catherine C. Y. Chang,Elena Bryleva,Stephanie Murphy,Maximillian A. Rogers
申请号：
US13605206
公开号：
US08802646B2
申请日:
2012.09.06
申请国别(地区):
US
年份:
2014
代理人:
摘要：
The present invention features methods for decreasing the size and density of amyloid plaques, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimers disease by selectively inhibiting the activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.
来源网站：
中国工程科技知识中心
来源网址：
http://www.ckcest.cn/home/
相关专利
Method of selectively inhibiting the activity of ACAT1 in the treatment of Alzheimers disease
AMYLOID BINDING AGENTS
monoclonal antibody, light chain and heavy chain variable regions, isolated cdr, polynucleotide, therapeutic composition, methods for treating disease and disorder, for producing an antibody, for treating or alleviating the effects of disease and disorder, for reducing plaque burden in an individual's brain, to reduce the amount of plaque in an individual's brain, to decrease the total amount of soluble spruce in an individual's brain, to retain or increase an individual's cognitive memory capacity, to diagnose from or to diagnose a predisposition to an amyloid-associated disease or condition
pharmaceutical composition, and methods for reducing plaque loading in a patient's retinal ganglion cell layer, for reducing the amount of plaque in a patient's retinal ganglion cell layer, for decreasing the total amount of soluble beta-amyloid in the patient layer of a patient's retinal ganglion to prevent, treat or alleviate the effects of an eye disease associated with pathological abnormalities / changes in visual system tissues, to diagnose a predisposition to an eye disease associated with pathological abnormalities / changes in system tissue to monitor for minimal residual ocular disea
pharmaceutical composition, and methods for reducing plaque burden in an animal's retinal ganglion cell layer, for reducing the amount of plaque in an animal's retinal ganglion cell layer, for decreasing the total amount of soluble beta-amyloid retinal ganglion cell layer of an animal to prevent, treat and / or alleviate the effects of eye disease associated with pathological abnormalities / changes in visual system tissue, to monitor minimal residual eye disease associated with pathological abnormalities / changes in visual system tissues, to predict a patient's responsiveness, and to retain
